| |
|
|
| |
Alzheimer’s disease |
|
| |
|
|
| |
Title: |
Alzheimer’s disease |
|
|
|
| |
|
|
|
| |
Summary |
|
| |
|
|
| |
You are been asked to participate in this research study of the investigational drug, Dimebon, because you have been diagnosed with Alzheimer’s disease. Alzheimer’s disease is a disease of the brain that destroys brain cells and causes problems with memory, thinking and behavior.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of Dimebon compared to placebo (inactive substance) in subjects with moderate to severe stages of Alzheimer’s disease.
|
|
| |
 |
|
| |
How Can You Qualify? |
|
| |
|
|
| |
The researchers at Princeton Medical Institute are seeking for men and women 50 years old and older taking Aricept. Participants must to have a family member or caregiver who can attend appointments during research study. Other criteria for eligibility will be discussed with interested persons, without obligation, when calling the telephone number listed below.
|
|
| |
|
|
| |
Principal Investigator |
|
| |
|
|
| |
Jeffrey T. Apter, MD
|
|
| |
|
|
| |
Contact |
|
| |
|
|
| |
Benjamin Shechet, CRC
-
(609)921-6050
|
|
| |
|
|
| |
Location |
|
| |
|
|
| |
GMI Corporate/Princeton Medical Institute - Princeton, New Jersey
|
|
| |
|
|
| |
 |
|
|
